Co-Managing Patients with Type 1 Diabetes and Cancer

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Current Diabetes Reports

• Publication date

  2016-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11892-016-0766-yPMID 27319323
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The American Diabetes Association’s (ADA’s) standards of medical care in diabetes (2018): diagnostics and treatment of diabetes mellitus

  2018cited by this paper
• Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.

  2017cited by this paper
• Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals

  2016cited by this paper
• Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies

  2016cited by this paper
• Standards of Medical Care in Diabetes—2016: Summary of Revisions

  2015cited by this paper
• Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis.

  2015cited by this paper
• Response to Comment on Hughes et al. An Early Pregnancy HbA1c ≥5.9% (41 mmol/mol) Is Optimal for Detecting Diabetes and Identifies Women at Increased Risk of Adverse Pregnancy Outcomes. Diabetes Care 2014;37:2953–2959

  2015cited by this paper
• Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes

  2015cited by this paper
• Correlation of early postoperative blood glucose levels with postoperative complications, hospital costs, and length of hospital stay in patients with gastrointestinal malignancies

  2015cited by this paper
• Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy

  2015cited by this paper
• State-of-the-art acute and chronic GVHD treatment

  2015cited by this paper
• Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition

  2015cited by this paper
• Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report

  2015cited by this paper
• Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010.

  2015influential reference
• Glycemic control and excess mortality in type 1 diabetes.

  2015cited by this paper
• Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

  2014cited by this paper
• The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia

  2014cited by this paper
• Safe and Effective Dosing of Basal–Bolus Insulin in Patients Receiving High-Dose Steroids for Hyper-Cyclophosphamide, Doxorubicin, Vincristine, and Dexamethasone Chemotherapy

  2014cited by this paper
• Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment

  2014cited by this paper
• Glycemic control and excess mortality in type 1 diabetes.

  2014cited by this paper
• Cohort Study of Insulin Glargine and Risk of Breast, Prostate, and Colorectal Cancer Among Patients With Diabetes

  2013cited by this paper
• Do corticosteroids provide analgesic effects in cancer patients? A systematic literature review.

  2013cited by this paper
• Management of hyperglycemia in diabetic patients with hematologic malignancies during dexamethasone therapy.

  2013cited by this paper
• Does Insulin Glargine Increase the Risk of Cancer Compared With Other Basal Insulins?

  2013cited by this paper
• Glucocorticoid-Induced Hyperglycemia

  2013cited by this paper
• An insulin protocol for management of hyperglycemia in patients receiving parenteral nutrition is superior to ad hoc management.

  2012cited by this paper
• Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes

  2012cited by this paper
• Mortality After Incident Cancer in People With and Without Type 2 Diabetes

  2012cited by this paper
• Glucocorticoid-mediated BIM induction and apoptosis are regulated by Runx2 and c-Jun in leukemia cells

  2012cited by this paper
• Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up

  2012cited by this paper
• Evaluation of transient hyperglycemia in non-diabetic patients with febrile neutropenia.

  2012cited by this paper
• Diabetes and Cause-Specific Mortality in a Prospective Cohort of One Million U.S. Adults

  2012cited by this paper
• Hyperglycemia is associated with increased risk of morbidity and mortality after colectomy for cancer.

  2012cited by this paper
• Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline.

  2012cited by this paper
• Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes

  2012cited by this paper
• A Prospective Study of the Associations Between Treated Diabetes and Cancer Outcomes

  2011cited by this paper
• Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

  2011cited by this paper
• Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death

  2011cited by this paper
• Comparison of 70/30 biphasic insulin with glargine/lispro regimen in non-critically ill diabetic patients on continuous enteral nutrition therapy.

  2011cited by this paper
• Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes Undergoing General Surgery (RABBIT 2 Surgery)

  2011cited by this paper
• Diabetes mellitus, fasting glucose, and risk of cause-specific death.

  2011cited by this paper
• Cancer risk among patients hospitalized for Type 1 diabetes mellitus: a population‐based cohort study in Sweden

  2010cited by this paper
• Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

  2009cited by this paper
• Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma.

  2009cited by this paper
• Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia

  2009cited by this paper
• Novel insights into glucocorticoid‐mediated diabetogenic effects: towards expansion of therapeutic options?

  2009cited by this paper
• Intensive versus conventional glucose control in critically ill patients.

  2009cited by this paper
• Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.

  2009cited by this paper
• Intensive versus Conventional Glucose Control in Critically Ill Patients

  2009cited by this paper
• The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients.

  2009cited by this paper
• Use of Continuous Glucose Monitoring to Estimate Insulin Requirements in Patients with Type 1 Diabetes Mellitus during a Short Course of Prednisone

  2008cited by this paper
• PERSISTENT OUTPATIENT HYPERGLYCEMIA IS INDEPENDENTLY ASSOCIATED WITH DECREASED SURVIVAL AFTER PRIMARY RESECTION OF MALIGNANT BRAIN ASTROCYTOMAS

  2008cited by this paper
• Antecedent Hyperglycemia Is Associated With an Increased Risk of Neutropenic Infections During Bone Marrow Transplantation

  2008cited by this paper
• Chemotherapy-Induced Nausea and Vomiting.

  2008cited by this paper
• Revisiting posttransplant survival for hepatitis C virus recipients.

  2007cited by this paper
• Pathophysiology of cancer cachexia: much more than host-tumour interaction?

  2007cited by this paper
• Mechanisms of PDL1-mediated regulation of autoimmune diabetes.

  2007cited by this paper
• Hyperglycemia During the Neutropenic Period Is Associated With a Poor Outcome in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation

  2007cited by this paper
• Role of Corticosteroids in Palliative Care

  2007cited by this paper
• Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin

  2006cited by this paper
• Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study

  2005cited by this paper
• Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus.

  2005cited by this paper
• Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphoblastic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate‐cytarabine regimen

  2004cited by this paper
• Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate–cytarabine regimen

  2004cited by this paper
• The response of leptin, interleukin-6 and fat oxidation to feeding in weight-losing patients with pancreatic cancer

  2004cited by this paper
• Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies.

  2002cited by this paper
• Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.

  2000cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Hormone responsive human breast cancer in long-term tissue culture: effect of insulin.

  1976cited by this paper

• A systematic review of glucocorticoid use in type 1 diabetes: Glycaemic effects and clinical management strategies.

  2026cites this paper
• A Practical Guide for the Management of Steroid Induced Hyperglycaemia in the Hospital

  2021cites this paper
• PROTOCOLO DE CUIDADOS BUCAIS PARA MUCOSITE ORAL EM TCTH UTILIZANDO PRODUTOS À BASE DE DIÓXIDO DE CLORO ESTABILIZADO 0,02%

  2017cites this paper